ClinicalTrials.gg
Active, not recruitingNCT06057038Updated Nov 3, 2026

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

A Phase 1 interventional study of GEN1042 and Pembrolizumab in Malignant Solid Tumor, sponsored by Genmab. Active, not recruiting at 3 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Genmab · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese participants. The main purpose is to assess the safety and tolerability of GEN1042 monotherapy or GEN1042 in combination in Japanese study participants with cancer.

Read the detailed description

This is an open-label, trial to evaluate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of GEN1042 in Japanese participants with malignant solid tumors. The trial consists of 2 parts: a GEN1042 Monotherapy Dose Escalation Part (phase 1a); and a Combination Therapy Part (phase 1b).

The purpose of Dose Escalation Part (phase 1a) is to evaluate GEN1042 as monotherapy in participants with non-central nervous system (non-CNS) malignant solid tumors.

The Combination Therapy Part (phase 1b) will evaluate GEN1042 in combination with pembrolizumab (pembro) or pembro along with the standard of care (SOC) chemotherapy in participants with head and neck squamous cell carcinoma (HNSCC) and non-small-cell lung cancer (NSCLC).

02

Conditions studied

  • Malignant Solid Tumor
03

In context

Lead sponsor

Genmab is the lead sponsor of 72 studies on the registry; 15 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 13 (57%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Must have according to v1.1.
  2. (ECOG) performance status score of 0-1.
  3. Acceptable organ and bone marrow function.
  4. Participant must have a of at least 3 months.

Key Exclusion Criteria:

  1. Has toxicities from previous anticancer therapies.
  2. Has rapidly progressing disease.
  3. Has a history of noninfectious pneumonitis/interstitial lung disease.
  4. Has a history of liver disease.
  5. Has had an allogeneic tissue/solid organ transplant or or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of GEN1042.
  6. Has any history of intracerebral arteriovenous malformation, cerebral aneurysm, or progressive or stroke.
  7. Has had major surgery within 4 weeks before Screening.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Monotherapy (non-CNS Malignant Solid Tumors): GEN1042

    Biological: GEN1042

  • Experimental
    Combination Therapy Cohort 1 [HNSCC]: GEN1042+Pembro+Chemotherapy

    Biological: GEN1042 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

  • Experimental
    Combination Therapy Cohort 2 [HNSCC and NSCLC]: GEN1042+Pembro

    Biological: GEN1042 · Drug: Pembrolizumab

  • Experimental
    Combination Therapy Cohort 3 [HNSCC]: GEN1042+Pembro+Chemotherapy

    Biological: GEN1042 · Drug: Pembrolizumab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

  • Experimental
    Combination Therapy Cohort 4 [HNSCC and NSCLC]: GEN1042+Pembro

    Biological: GEN1042 · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    Toxicities will be graded for severity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), version (v) 5.0.

    Time frame: During the first cycle (Cycle length = 21 days)

  2. Percentage of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.

    Time frame: From first dose until the end of the treatment (approximately 3 years)

Secondary outcomes

  1. Maximum (Peak) Plasma Concentration (Cmax) of GEN1042

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 years)

  2. Area Under the Concentration-time Curve (AUC) From Time Zero to Last Quantifiable Sample (AUClast) of GEN1042

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 years)

  3. Time to Reach Cmax (Tmax) of GEN1042

    Time frame: Predose and postdose at multiple timepoints up to end of treatment (approximately 3 years)

  4. Number of Participants with Anti-drug Antibodies (ADA) to GEN1042

    Serum samples will be screened for ADAs binding to GEN1042 and the titer of confirmed positive samples will be reported.

    Time frame: up to 3 years

  5. Objective Response Rate (ORR)

    ORR is defined as percentage of participants with a best overall response (BOR) (Complete Response (CR) or Partial Response (PR)) confirmed by a subsequent BOR of CR or PR at least 4 weeks later per response evaluation criteria in solid tumors (RECIST) v1.1 based on investigator assessment.

    Time frame: Up to 3 years

  6. Duration of Response (DOR)

    DOR only applies to participants whose confirmed BOR is CR or PR and is defined as time from the first documentation of objective tumor response (CR or PR) to the date of first disease progression (PD) or death per RECIST criteria v1.1 based on investigator assessment.

    Time frame: Up to 3 years

  7. Disease Control Rate (DCR)

    The DCR is defined as the percentage of participants with BOR of confirmed CR, confirmed PR, or Stable Disease (SD) per RECIST criteria v1.1 based on investigator assessment.

    Time frame: Up to 3 years

  8. Progression Free Survival (PFS)

    PFS is defined as the time from Day 1 in Cycle 1 to the first documented progression or death due to any cause per RECIST criteria v1.1 based on investigator assessment.

    Time frame: Up to 3 years

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Aug 2027, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2023
First posted
Sep 28, 2023
StartActual
Nov 24, 2023
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06057038
Lead sponsor
Genmab
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Sep 28, 2023
Start date
Nov 24, 2023
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Official
study director · Genmab

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tecaginlimab

Start the discussion